- Indication: Gout
- Enrollment Status: Enrollment Closed
- Protocol: HZNP-KRY-409
- Drug: KRYSTEXXA® (pegloticase)
- Sponsor: Horizon/Amgen
- Description: A Phase 4, Randomized, Double-blind, Multicenter Non-inferiority Trial Evaluating the Efficacy and Safety of Intravenous KRYSTEXXA® (pegloticase) Administered Every 4 Weeks Compared with KRYSTEXXA Administered Every 2 Weeks with Co-administration of Weekly Doses of Methotrexate, Followed by an Open-label Extension, in Participants with Uncontrolled Refractory Gout (FORWARD II)
